Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.

PubWeight™: 2.27‹?› | Rank: Top 2%

🔗 View Article (PMC 3387987)

Published in Clin Cancer Res on August 09, 2011

Authors

Judith Manola1, Patrick Royston, Paul Elson, Jennifer Bacik McCormack, Madhu Mazumdar, Sylvie Négrier, Bernard Escudier, Tim Eisen, Janice Dutcher, Michael Atkins, Daniel Y C Heng, Toni K Choueiri, Robert Motzer, Ronald Bukowski, International Kidney Cancer Working Group

Author Affiliations

1: Eastern Cooperative Oncology Group Statistical Office, Dana-Farber Cancer Institute, Boston, MA 02215, USA. jmanola@jimmy.harvard.edu

Articles citing this

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19

Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol (2012) 1.19

Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS One (2013) 1.17

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer (2013) 1.12

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer (2013) 0.99

Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep (2012) 0.89

Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma. Can Urol Assoc J (2014) 0.87

Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol (2015) 0.85

Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin Med Insights Oncol (2011) 0.82

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br J Cancer (2012) 0.82

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. Br J Cancer (2013) 0.81

Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors. Onco Targets Ther (2013) 0.81

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci (2015) 0.80

A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. Acta Oncol (2015) 0.80

Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol (2012) 0.79

Prognostic factors of overall survival in renal cancer patients - single oncological center study. Cent European J Urol (2013) 0.79

Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell Int (2014) 0.78

Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. World J Urol (2016) 0.76

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib. J Cancer Res Clin Oncol (2017) 0.75

Does a reasonable treatment approach beyond second-line exist? EJC Suppl (2013) 0.75

Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. J Kidney Cancer VHL (2017) 0.75

Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma. Chin J Cancer (2017) 0.75

Biomarkers for tyrosine kinase inhibitors in renal cell cancer. Transl Androl Urol (2012) 0.75

A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma. J Clin Med Res (2017) 0.75

Re: prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. J Urol (2012) 0.75

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer (2016) 0.75

Therapeutic challenges in advanced renal cell carcinoma. Clin Pract (Lond) (2013) 0.75

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience (2016) 0.75

Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. Mol Clin Oncol (2017) 0.75

Current Management Options in Metastatic Renal Cell Cancer. Oncol Rev (2017) 0.75

Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. Med Oncol (2017) 0.75

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. Br J Cancer (2017) 0.75

Articles cited by this

Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28

Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25

Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst (2006) 6.58

A new measure of prognostic separation in survival data. Stat Med (2004) 4.98

Building multivariable regression models with continuous covariates in clinical epidemiology--with an emphasis on fractional polynomials. Methods Inf Med (2005) 2.54

Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer (2003) 2.18

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2010) 2.06

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res (1988) 1.84

Validation techniques for logistic regression models. Stat Med (1991) 1.82

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50

Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer (2010) 1.44

Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol (2000) 1.44

Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer (1994) 1.02

Articles by these authors

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ (2009) 19.23

Multiple imputation using chained equations: Issues and guidance for practice. Stat Med (2010) 17.36

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25

Renal cell carcinoma. Lancet (2009) 6.92

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64

Prognosis and prognostic research: validating a prognostic model. BMJ (2009) 6.54

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23

Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82

The design of simulation studies in medical statistics. Stat Med (2006) 5.30

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27

The cost of dichotomising continuous variables. BMJ (2006) 5.12

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05

Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68

Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60

Prognosis and prognostic research: what, why, and how? BMJ (2009) 4.46

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43

Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ (2009) 4.38

Imputing missing covariate values for the Cox model. Stat Med (2009) 4.31

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet (2008) 4.11

Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79

Perioperative outcomes after unilateral and bilateral total knee arthroplasty. Anesthesiology (2009) 3.66

Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49

Perioperative comparative effectiveness of anesthetic technique in orthopedic patients. Anesthesiology (2013) 3.45

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19

An integrated physical and genetic map of the rice genome. Plant Cell (2002) 3.07

Risk prediction models: II. External validation, model updating, and impact assessment. Heart (2012) 3.05

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer (2007) 3.00

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93

Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg (2009) 2.93

CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax (2011) 2.88

Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79

Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart (2012) 2.76

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73

Inpatient falls after total knee arthroplasty: the role of anesthesia type and peripheral nerve blocks. Anesthesiology (2014) 2.73

How should variable selection be performed with multiply imputed data? Stat Med (2008) 2.65

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol (2007) 2.57

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50

Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med (2007) 2.46

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44

Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging (1999) 2.43

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther (2008) 2.42

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40

NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol (2002) 2.39

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37

A simple algorithm to predict incident kidney disease. Arch Intern Med (2008) 2.36

Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer (2007) 2.34

A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcome. Stat Methods Med Res (2007) 2.31

A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol (2005) 2.30

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26

Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med (2004) 2.26

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 2.25

Development and validation of a prediction model with missing predictor data: a practical approach. J Clin Epidemiol (2009) 2.24

Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol (2009) 2.23

Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg (2008) 2.21

Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18